

José López-Fernández*, David Fernández-San Millán,
Antonio Navarro-Sánchez,
Juan Ramón Hernández Hernández

*Servicio de Cirugía General y del Aparato Digestivo,
Complejo Hospitalario Universitario Insular-Materno
Infantil, Las Palmas de Gran Canaria, Spain*

*Corresponding author.

E-mail address: jlopezfdz89@gmail.com

(J. López-Fernández).

2444-3824/

© 2016 Elsevier España, S.L.U., AEEH and AEG. All rights reserved.

Rectal neuroendocrine tumor with an exceptional behaviour[☆]



Tumor neuroendocrino de recto de comportamiento excepcional

Neuroendocrine tumors are malignancies that derive from the diffuse endocrine system of the intestine, which secrete

up to 40 different cytokines and hormones.^{1,2} 75% manifest in the digestive system, 34% of which in the rectum, where they tend to be asymptomatic and present in the form of sessile masses or thinning of the rectal wall.³ Prognosis will depend on the extent of the vascular or lymphatic invasion. Tumors measuring less than 1 cm present metastasis in fewer than 3% of cases, while the rate of metastasis for tumors larger than 2 cm increases to up to 70%. Tumor size




Figure 1 (A) Lower echo-endoscopy revealing perirectal lymphadenopathy. The resulting biopsy was positive for carcinoid tumor. (B) Octreoscan with pathological uptake in the left perirectal area.

[☆] Please cite this article as: Nutu OA, Brandáriz L, Pérez Carreras M, García-Borda J, Perea J. Tumor neuroendocrino de recto de comportamiento excepcional. *Gastroenterol Hepatol.* 2017;40:351–352.

greater than 2 cm, invasion of the muscular layer, mitotic index greater than 2%, the degree of differentiation and positive resection margins^{4,5} are all predictive factors for poor prognosis.

We present the case of a 46-year-old male patient on anticoagulation therapy due to ischaemic stroke. Following episodes of rectorrhagia, a colonoscopy was performed that revealed a 6 mm yellowish lesion presenting erosion on its surface, 6 cm from the anal margin, consistent with a well-differentiated grade 1 neuroendocrine tumor. The patient was positive for glucagon with a mitotic index (Ki-67) of less than 2% and invasion of the deep border of the submucosal resection. Chromogranin A blood levels were below 100 ng/ml. An extension study was conducted that revealed a right lung nodule of less than 1 cm and two lymphadenopathies, one of which measuring 18 mm in the left pararectal area and the other measuring 9 mm in the presacral space. Endoscopic ultrasound-guided fine-needle aspiration of the pararectal lymphadenopathy was performed, confirming the presence of a neuroendocrine tumor (Fig. 1A). Lower anterior resection surgery with total mesorectal excision was performed. The anatomopathological findings of the surgical specimen were without malignancy, with negative edges, without lymphovascular invasion but with metastasis of the grade 1 neuroendocrine tumor in two lymph nodes (T1N1). Adjuvant therapy with somatostatin was started and a whole-body scintigraphy performed after two months, which revealed a pathological accumulation of radioactive material in the left pararectal area (Fig. 1B). It was therefore decided to perform surgery to remove the lymphadenopathy. The anatomopathological study found metastasis of the well-differentiated neuroendocrine tumor. Another scintigraphy was performed after two months, with no evidence of uptake at any level.

In the case that we have presented, the tumor was well-differentiated, Ki-67, less than 2%, less than 1 cm, did not extend beyond the submucosa and with negative resection margins in the specimen, but with nodal disease (stage IIIB). Although the treatment indicated for tumors less than 1 cm that do not extend beyond the submucosa is endoscopic resection or submucosal dissection, the patient did not undergo either of these as he presented with nodal disease. According to Kasuga et al.,⁶ the independent risk factor for lymph node metastases in rectal neuroendocrine tumors smaller than 10 mm is venous invasion, while Zhou et al.⁷ also propose tumors with a central depression.

The endoanal ultrasound ascertained the depth of the tumor invasion and the presence of metastasis in the perirectal lymph nodes. The CT scan was performed to forecast involvement of the pelvic lymph nodes prior to surgery, with 95% sensitivity.⁸ Although the incidence of lymph node metastasis in neuroendocrine tumors smaller than 1 cm is low, treatment of this tumor type should not end with endoscopic resection and/or follow-up, as the two procedures referred to above (endoanal ultrasound and CT scan) may

detect sub-centimetre lymph node metastasis, which would affect the treatment administered. After this kind of diagnosis, subsequent follow-up is recommended with imaging and marker tests at three and six months. Our case illustrates the need for a personalised approach to these patients given the risk of lymph node metastasis, regardless of phenotypical or molecular characteristics to the contrary. Given its atypical nature, our case was discussed by a specialist tumor committee and it was decided to conduct follow-up at two months. Given the unpredictable biological behaviour of these tumors, follow-up after resection should be a lot more comprehensive than is regularly practised, at least in these types of malignancy.

References

1. McDermott FD, Heeney A, Courtney D, Mohan H, Winter D. *Surg Endosc.* 2014;28:2020–6.
2. Kloppel G, Perren A, Heitz P. The gastroenteropancreatic neuroendocrine cell system and its tumours: the WHO classification. *Ann N Y Acad Sci.* 2004;1014:13–27.
3. Chi Y, Du F, Zhao H, Wang JW, Cai JQ. Characteristics and long-term prognosis of patients with rectal neuroendocrine tumors. *World J Gastroenterol.* 2014;20:16252–7.
4. De Mestier L, Brixi H, Gincul R, Ponchon T, Cadiot G. Updating the management of patients with rectal neuroendocrine tumors. *Endoscopy.* 2013;45:1039–46.
5. Kwaan MR, Goldberg JE, Bleday R. Rectal carcinoid tumors: review of results after endoscopic and surgical therapy. *Arch Surg.* 2008;143:471.
6. Kasuga A, Chino A, Uragami N, Kishihara T, Igarashi M, Fujita R, et al. Treatment strategy for rectal carcinoids: a clinicopathological analysis of 229 cases at a single cancer institution. *J Gastroenterol Hepatol.* 2012;27:1801–7.
7. Zhou X, Xie H, Xie L, Li J, Fu W. Factors associated with lymph node metastasis in radically resected rectal carcinoids: a systematic review and meta-analysis. *J Gastrointest Surg.* 2013;17:1689–97.
8. Yano H, Saito Y, Takeshita E, Miyake O, Ishizuka N. Prediction of lateral pelvic node involvement in low rectal cancer by conventional computed tomography. *Br J Surg.* 2007;94:1014–9.

Oana A. Nutu^{a,*}, Lorena Brandáriz^a, Mercedes Pérez Carreras^b, Javier García-Borda^a, José Perea^a

^a *Unidad de Coloproctología, Servicio de Cirugía General y del Aparato Digestivo, Hospital Universitario 12 de Octubre, Madrid, Spain*

^b *Servicio de Medicina del Aparato Digestivo, Hospital Universitario 12 de Octubre, Madrid, Spain*

* Corresponding author.

E-mail address: oana.nutu@hotmail.com (O.A. Nutu). 2444-3824/

© 2016 Elsevier España, S.L.U., AEEH and AEG. All rights reserved.